Cargando…
Response to Letter to the Editor: “Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes”
Autores principales: | Tsang, Venessa H M, McGrath, Rachel T, Clifton-Bligh, Roderick J, Scolyer, Richard A, Jakrot, Valerie, Guminski, Alexander D, Long, Georgina V, Menzies, Alexander M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170215/ https://www.ncbi.nlm.nih.gov/pubmed/32188993 http://dx.doi.org/10.1210/clinem/dgaa144 |
Ejemplares similares
-
Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors
por: Muir, Christopher Alan, et al.
Publicado: (2021) -
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
por: Wu, Linda, et al.
Publicado: (2021) -
Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
por: Tsang, Venessa, et al.
Publicado: (2022) -
Letter to the Editor From Grill et al: “Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial”
por: Grill, Valdemar, et al.
Publicado: (2021) -
Response to the Letter to the Editor from Valdemar Grill et al: “Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial”
por: Liang, Huiying, et al.
Publicado: (2021)